الرسائل الموجهة للمختصين الصحيين
الرسائل الموجهة للمختصين الصحيين
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| AVASTIN® - Bevacizumab | 2013-04-07 | Cases of Necrotizing Fasciitis Reported with AVASTIN |
|
| MabThera® - Rituximab | 2013-04-01 | Risk of Toxic Epidermal Necrolysis And Stevens-Johnson-Syndrome |
|
| SPRYCEL® - Dasatinib | 2013-01-27 | Risk of (PAH) Pulmonary Arterial Hypertension |
|
| Valdoxan® - Agomelatine | 2013-01-21 | Risk of hepatotoxicity with agomelatine |
|
| Arava® - leflunomide | 2012-12-23 | Risk of hepatotoxicity Risk of serious birth defects |
|
| Wellbutrin®/Zyban® - bupropion | 2012-12-15 | Increased risk of congenital cardiovascular malformations |
|
| Gilenya® - fingolimod | 2012-12-09 | Cardiovascular adverse events after the first dose of Gilenya® |
|
| Zofran® - ondansetron | 2012-04-14 | Risk of developing abnormal changes in the electrical activity of the heart |
|
| Avastin® - bevacizumab | 2012-03-03 | Reports of severe infectious endophthalmitis following unapproved intravitreal injection use |
|
| Actos® - pioglitazone | 2011-12-20 | Risk of bladder cancer |
|